Online ISSN: 2515-8260

Keywords : chronic disease

Bilayer Drug Delivery: A Promising Role In Rheumatoid Arthritis

Urvashi Negi, Kapil Kalra, Vinita Chauhan, Saumya Mishra, Abhishek Chauhan

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 8541-8545

Bilayer tablet is an advanced form of tablet design and it’s very useful in treatment of chronic diseases and their associated adverse disorders. It’s also helpful in treatment where more than one drug is indulged eg. Diabetic, Rheumatoid arthritis. Now a day’s many type of marketed bilayer preparation are available which shows a tremendous result to treat chronic disease. Bilayer tablets are used to control different types of successful drug release rate. In this review we discussed on the rheumatoid arthritis, possible treatment, how to bi-layer tablet helpful in RA treatment, bilayer formulation methods, etc. pharmaceutical incompatibility, sustain release, immediate release

To compare various biomarkers in head and neck squamous cell carcinoma pre and post treatment

Dr. SumitDokwal,Dr. Rajesh Kumar,Dr. Ajit Singh, Dr. KiranDahiya, Dr. Rajeev Atri,Dr. RakeshDhankhar

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2979-2990

Introduction: In India, head and neck cancer is the commonest cancer in men and in both
sexes.In most cases, due to extensive loco-regional involvement, poor general condition of the
patient, or co-morbid conditions, curative treatment is not possible. Aims & Objectives: To
know serum Magnesium levels in patients of head and neck squamous cell carcinoma before
and after treatment. Data & Methodology: This study was conducted in the Department of
Biochemistry in collaboration with Department of Radiotherapy, Pt BD Sharma Post
Graduate Institute of Medical Sciences, Rohtak, India. For the completion of the study, 30
newly diagnosed patients with HNSCC, and 30 age and sex matched healthy individuals were
taken. Chi-square and t-test were applied to know the association and comparison between
case and control group respectively. Results: The subjects were categorized into three groups
such asgroup A- Pretreatment cases, group B- Post-treatment cases and group C- Controls.
Plasma glucose in group A was 84.73 ± 2.97 (57-115)mg/dL. Plasma glucose in group B was
103.46±5.15 (61-171) mg/dL whereas group C plasma glucose was 84.73±2.97 (57-115)
mg/dL. p value between group A and group B was 0.001. It was found significant difference
between cases before and after treatment in glucose levels. The levels in cases before treatment
were found significantly different from controls regarding ALT, Albumin, total protein and
TBIL with p values 0.015, 0.020 respectivelyConclusions: It was found highly significant
difference between case and control groups especially for LDL, Protein and Calcium wise
classification respectively.